Corix Bioscience

Corix Bioscience EBITDA per Share

The EBITDA per Share of Corix Bioscience (CXBS) as of Oct 9, 2026 is -32.89 USD. In the previous year, EBITDA per Share was -21.24 USD — a change of 54.84% (lower).

EBITDA per Share

-32.89USD

YoY

54.84%

Last updated:

EBITDA per Share of Corix Bioscience is 2016 -32.89 USD. EBITDA per Share of Corix Bioscience was 2015 -21.24 USD. It decreases by 54.84% lower compared to the previous year.

The Corix Bioscience EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2014
-0.47 USD
Jan 1, 2015
-21.24 USD
Jan 1, 2016
-32.89 USD
The Corix Bioscience EBITDA per Share history
YEAREBITDA per ShareYoY
-32.89USD+54.84%
-21.24USD+4,463.02%
-0.47USD—
Access this data via the Eulerpool API

Corix Bioscience Stock analysis

What does Corix Bioscience do? Corix Bioscience is a company specialized in the production of cannabinoid-based products. It was founded in 2014 under the name American Housing Income Trust, a holding company focused on the American real estate market. In 2017, the company decided to restructure and change its name to Corix Bioscience. Since then, the company has become one of the leading manufacturers of CBD oils and other cannabinoid-based products. Corix Bioscience's business model is based on state-of-the-art technologies and innovation in the cannabinoid industry. The company collaborates with other firms to develop new products tailored to patient needs. The company aims to provide patients with a natural and safe alternative to conventional medical therapy. Corix Bioscience has five divisions. These include "Corix Bioscience," which focuses on the development of CBD-based products for the European market. "Corix Health" develops cannabinoid-based products specifically tailored to patient needs. "Subsidiaries" is responsible for collaborating with other companies to expand the product offering. "Licensing" offers licenses for technologies and rights to use innovative products. "Research and Development" focuses on advancing research and technologies in the cannabinoid industry. One of Corix Bioscience's most well-known products is CBD oil. It is extracted from specially bred hemp plants and is used for pain relief, anxiety, and other ailments. The company also offers CBD-based cosmetic products and food. Corix Bioscience is headquartered in Fresno, California, and is now internationally active. The company places special emphasis on the quality of its products and uses only natural and certified ingredients. Corix Bioscience advocates for fair and sustainable production and focuses on environmental protection and sustainability. The future prospects for Corix Bioscience are promising. The company operates in a forward-thinking market, focusing on innovation and sustainability. The developments in the market for cannabinoid-based products allow Corix Bioscience to expand its portfolio and offer more patients a natural alternative to conventional medical therapy. Corix Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Corix Bioscience stock

EBITDA per Share of Corix Bioscience is -32.89 USD in 2016.

EBITDA per Share of Corix Bioscience changed from -21.24 USD to -32.89 USD, representing a 54.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Corix Bioscience since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

Income Statement — Corix Bioscience

All Key Metrics — Corix Bioscience